1. Home
  2. SOWG vs ACRV Comparison

SOWG vs ACRV Comparison

Compare SOWG & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

HOLD

Current Price

$2.99

Market Cap

63.4M

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.56

Market Cap

68.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOWG
ACRV
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Medicinal Chemicals and Botanical Products
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.4M
68.5M
IPO Year
2011
2022

Fundamental Metrics

Financial Performance
Metric
SOWG
ACRV
Price
$2.99
$1.56
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
17.2K
460.7K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$1.20
52 Week High
$4.45
$3.56

Technical Indicators

Market Signals
Indicator
SOWG
ACRV
Relative Strength Index (RSI) 44.31 42.06
Support Level $0.38 $1.38
Resistance Level $4.43 $2.20
Average True Range (ATR) 0.27 0.12
MACD -0.12 -0.04
Stochastic Oscillator 23.04 19.46

Price Performance

Historical Comparison
SOWG
ACRV

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: